Director sold ~$340K of Regeneron Pharmaceuticals
Scheduled in advanceLoading…
Reporting person on SEC Form 4
Kathryn Guarini
Director
Disclosures on record
8
Companies involved
1
Disclosure history
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Director sold ~$320K of Regeneron Pharmaceuticals
Scheduled in advanceDerivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.